LAKE FOREST, Ill., Nov. 17, 2014 /PRNewswire/ -- The board of directors and employees of Hospira, Inc. ( NYSE: HSP) today expressed their deepest sorrow over the loss of Connie R. Curran, R.N., Ed. D, one of the company's founding board members. Dr. Curran had served as a member of the Hospira Board since 2004, providing invaluable contributions to the business through her strategic leadership, exceptional command of the healthcare industry and shared passion for the company's commitment to putting patients first.
"Our hearts are heavy with the loss of our dear friend and sage advisor," said John C. Staley, chairman, Hospira. "Connie had a rare combination of brilliance, humor, humility and passion that touched every person fortunate enough to cross her path. We were privileged to have known and worked with such a remarkable woman and mourn our loss."
Added F. Michael Ball, Hospira's chief executive officer, "With talents and achievements too numerous to count, it's Connie's heart, generosity and vibrant spirit that made her a unique and powerful force – from the board room to the patient bedside and everywhere in between. Connie made everyone she interacted with feel special and richer for the experience, and we have all benefited from our association with her both personally and professionally -- she will be greatly missed."
To honor Dr. Curran's legacy and wishes, the Hospira Foundation is directing a donation to the Breast Cancer Research Foundation.
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 19,000 employees. Learn more at www.hospira.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains, or may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological, manufacturing, supply, quality and other factors that may affect Hospira's operations, and may cause actual results to be materially different from expectations also include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
SOURCE Hospira, Inc.